1132 completed, 253 unknown, 198 recruiting, 187 terminated. 499 Phase 2, 387 Not applicable, 330 Phase 1, 282 Phase 3, 153 Phase 4.
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss Personalised Remapping Training, RSVP personalized remappi, Reading text in the wild with remapping - Macular Degeneration, Central Visual Impairment | Not applicable | Not yet recruiting | University of Minnesota | 216 | 2027-06-01 | 2026-10-29 |
| GA001 Injection in Retinitis Pigmentosa GA001, Sham injection - Retinitis Pigmentosa (RP) | Phase 2 | Not yet recruiting | GenAns Biotechnology Co., Ltd | 12 | 2027-04-01 | 2026-11-17 |
| Safety and Clinical Performance of the LENTISĀ® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation. Intraocular Lens - Cataract, AMD - Age-Related Macular Degeneration | Not applicable | Not yet recruiting | Teleon Surgical B.V. | 35 | 2027-02-01 | 2026-11-04 |
| Non-invasive Ultrasound Retinal Stimulation for Vision Restoration Non-invasive ultrasound retinal stimulation Device - Age-Related Macular Degeneration, Retinitis Pigmentosa | Not applicable | Not yet recruiting | University of Southern California | 5 | 2027-01-10 | 2026-01-08 |
| MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration. Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD) | Not yet recruiting | IRCCS San Raffaele | 160 | 2027-01-02 | 2026-09-29 | |
| Prevalence of Age-Related Macular Degeneration in Assiut University Hospitals OCT - clear - Age-Related Macular Degeneration (AMD) | Not yet recruiting | Assiut University | 90 | 2027-01-01 | 2026-10-21 | |
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| Njinsky Ambispective Cellular Product Safety and Outcomes Registry Umbilical Cord Mesenchymal Stem Cells, Stromal Vascular fraction - Retinitis Pigmentosa (RP), Autism Disorder | Not yet recruiting | Njinsky Medical Centre | 1200 | 2026-12-01 | 2026-11-17 | |
| Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography - Geographic Atrophy | Not applicable | Enrolling by invitation | University of Wisconsin, Madison | 10 | 2026-11-05 | 2026-10-26 |
| MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration Transpalpebral microcurrent electrical stimulation - Age-Related Macular Degeneration (AMD) | Not applicable | Not yet recruiting | Clarity Eye Institute | 50 | 2026-11-04 | 2026-11-04 |
| A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants CITY-RBP4, Placebo - Stargardt Disease 1, STGD1 | Phase 1 | Recruiting | City Therapeutics | 48 | 2026-11-04 | 2026-11-12 |
| OCT Macula Biomarkers Before Silicone Oil Removal and Visual Outcome After Silicone Oil Removal Retinal Detachment, Macular Edema | Not yet recruiting | Assiut University | 30 | 2026-11-01 | 2026-10-08 | |
| Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID, Placebo 2drops TID - wetAMD, Age Related Macular Degeneration | Phase 2 | Not yet recruiting | SCAI Therapeutics | 50 | 2026-11-01 | 2026-05-26 |
| Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment Active hf-tRNS., Placebo/sham hf-tRNS - Retinitis Pigmentosa (RP), Rod Cone Dystrophy | Not applicable | Recruiting | University of Waterloo | 20 | 2026-11-01 | 2026-11-03 |
| A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD) | Phase 2 | Not yet recruiting | Everest Medicines (China) Co.,Ltd. | 244 | 2026-11-01 | 2026-11-05 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD) 1 % Bevemipretide, 2% Bevemipretide, Vehicle - Dry AMD, Age-Related Macular Degeneration (AMD) | Phase 2 / Phase 3 | Not yet recruiting | Mighty Therapeutics, Inc. | 300 | 2026-11-01 | 2026-11-09 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-23 | 2026-11-10 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) OLN324, Ranibizumab - Wet Age-related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 400 | 2026-10-15 | 2026-09-11 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) OLN324, Aflibercept - Wet Age Related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 500 | 2026-10-15 | 2026-09-11 |
| Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration Photobiomodulation Therapy, Sham Photobiomodulation - AMD - Age-Related Macular Degeneration | Not applicable | Recruiting | Fondazione G.B. Bietti, IRCCS | 67 | 2026-10-09 | 2026-11-16 |
Showing 20 of 2018. Sign in to see all of them.
Macular Degeneration (1174) · Macular Edema (418) · Retinitis Pigmentosa (270) · Geographic Atrophy (179) · Diabetic Retinopathy (160) · Retinal Vein Occlusion (155) · Choroidal Neovascularization (138) · Retinal Diseases (136) · Eye Diseases (99) · Wet Macular Degeneration (93) · Vision Disorders (89) · Diabetes Mellitus (66) · Stargardt Disease (66) · Glaucoma (52)
Eye Diseases (1919) · Retinal Diseases (1882) · Macular Degeneration (527) · Eye Diseases, Hereditary (424) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (382) · Genetic Diseases, Inborn (371) · Pathological Conditions, Signs and Symptoms (371) · Cardiovascular Diseases (308) · Vascular Diseases (307) · Retinal Dystrophies (279) · Nervous System Diseases (219) · Uveal Diseases (218) · Endocrine System Diseases (208) · Pathologic Processes (199)
Ranibizumab (263) · aflibercept (151) · Bevacizumab (81) · salicylhydroxamic acid (63) · Dexamethasone (51) · Calcium Dobesilate (40) · Triamcinolone Acetonide (34) · Verteporfin (32) · pegaptanib (26) · brolucizumab (22) · Triamcinolone (21) · Tomography, Optical Coherence (18) · Lutein (15) · Photochemotherapy (14) · Intravitreal Injections (13)
National Eye Institute (NEI) (90) · Novartis Pharmaceuticals (67) · Allergan (38) · Bayer (38) · Medical University of Vienna (28) · Genentech, Inc. (26) · Johns Hopkins University (25) · Notal Vision Ltd. (21) · Alcon Research (20) · Hoffmann-La Roche (16) · Pfizer (16) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (15) · Duke University (14) · University of Sao Paulo (13) · GlaxoSmithKline (12)
United States (909) · France (192) · Germany (189) · United Kingdom (176) · Canada (134) · Italy (130) · China (114) · Australia (113) · Austria (104) · Spain (104) · Israel (89) · Hungary (72) · Switzerland (71) · Poland (65) · South Korea (64)
Emily Y Chew, M.D. (9) · Pablo Velazquez-Martin, MD (8) · Peter A Campochiaro, MD (6) · Jennifer Henrick, RN, MS (5) · Mohamed Genead, MD (5) · Peter Campochiaro, MD (5)
PMID 37314061, PMID 37702300, PMID 32374423, PMID 32573764, PMID 40547876, PMID 22281388, PMID 25458728, PMID 30957581, PMID 32844399, PMID 34934034, PMID 39758130, PMID 23049090, PMID 23084240, PMID 23706949, PMID 25677668, PMID 30194931, PMID 33206392, PMID 33331670, PMID 35085502, PMID 36246941, PMID 36912792, PMID 37261916, PMID 39102242, PMID 39207600, PMID 11297486, PMID 15808240, PMID 17021318, PMID 17021319, PMID 19255158, PMID 19365036, PMID 19506188, PMID 20189654, PMID 20378094, PMID 20683380, PMID 20688734, PMID 20920825, PMID 21296824, PMID 21320967, PMID 21546089, PMID 21794843, PMID 22234714, PMID 22559899, PMID 22562517, PMID 22761263, PMID 22965590, PMID 23009891, PMID 23361508, PMID 23415775, PMID 23453513, PMID 23668681
2014 (12), 2019 (11), 2018 (7), 2025 (6), 2009 (5), 2017 (5), 2015 (4), 2016 (4), 2005 (2), U10EY014231 (2), U10EY018817 (2), U10EY024527 (2), 1UG1EY033293 (1), 2023 (1), I01RX004563 (1)